In contrast with other reports associating IL-6 augmentation with a poor outcome (42) or SIRS (43), recent reports show that IL-6 is not a definitive biomarker to determine systemic inflammation (42). The gene discussed is IL6; the disease is systemic inflammatory response syndrome.